OMARINI, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.833
EU - Europa 5.454
AS - Asia 5.278
SA - Sud America 798
AF - Africa 168
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 12
Totale 21.576
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.631
IT - Italia 1.550
SG - Singapore 1.537
CN - Cina 1.281
GB - Regno Unito 959
IE - Irlanda 833
VN - Vietnam 637
HK - Hong Kong 618
BR - Brasile 577
DE - Germania 509
SE - Svezia 368
FR - Francia 250
RU - Federazione Russa 205
FI - Finlandia 199
BD - Bangladesh 195
IN - India 174
ID - Indonesia 145
KR - Corea 142
UA - Ucraina 113
CA - Canada 104
TR - Turchia 94
AR - Argentina 75
JP - Giappone 66
BG - Bulgaria 63
IQ - Iraq 62
NL - Olanda 61
MX - Messico 54
PL - Polonia 51
LT - Lituania 46
CO - Colombia 41
ES - Italia 41
TW - Taiwan 41
CL - Cile 36
ZA - Sudafrica 35
PK - Pakistan 34
EG - Egitto 33
AU - Australia 30
BE - Belgio 30
CZ - Repubblica Ceca 29
MY - Malesia 29
EC - Ecuador 27
AE - Emirati Arabi Uniti 25
AT - Austria 25
IR - Iran 23
MA - Marocco 23
SA - Arabia Saudita 21
VE - Venezuela 19
JO - Giordania 18
KE - Kenya 18
NP - Nepal 18
RO - Romania 18
PH - Filippine 15
TH - Thailandia 14
CH - Svizzera 13
MD - Moldavia 12
UZ - Uzbekistan 11
AZ - Azerbaigian 10
EU - Europa 10
PY - Paraguay 10
SY - Repubblica araba siriana 10
TN - Tunisia 10
DO - Repubblica Dominicana 9
HU - Ungheria 9
IL - Israele 9
CR - Costa Rica 8
JM - Giamaica 8
RS - Serbia 8
DZ - Algeria 7
GR - Grecia 7
AL - Albania 6
BH - Bahrain 6
NG - Nigeria 6
PE - Perù 6
PT - Portogallo 6
AO - Angola 5
ET - Etiopia 5
GH - Ghana 5
HN - Honduras 5
HR - Croazia 5
LB - Libano 5
MT - Malta 5
SK - Slovacchia (Repubblica Slovacca) 5
BO - Bolivia 4
CI - Costa d'Avorio 4
CY - Cipro 4
DK - Danimarca 4
GA - Gabon 4
KG - Kirghizistan 4
LV - Lettonia 4
NO - Norvegia 4
PS - Palestinian Territory 4
SI - Slovenia 4
IS - Islanda 3
KH - Cambogia 3
KZ - Kazakistan 3
LK - Sri Lanka 3
MK - Macedonia 3
NZ - Nuova Zelanda 3
OM - Oman 3
QA - Qatar 3
Totale 21.527
Salva come PNG Salva come JPEG
Città #
Ashburn 1.204
Singapore 1.016
Santa Clara 981
Dublin 828
Fairfield 636
Chandler 592
Hong Kong 592
San Jose 482
Dallas 476
Southend 420
Hefei 322
Houston 300
Council Bluffs 294
Woodbridge 294
Beijing 277
Nyköping 259
Seattle 255
Wilmington 241
Ann Arbor 227
Dearborn 215
New York 209
London 208
Ho Chi Minh City 201
Los Angeles 184
Cambridge 176
Helsinki 162
Modena 155
Jacksonville 147
The Dalles 147
Hanoi 143
Milan 136
Seoul 132
Chicago 129
Jakarta 108
Munich 105
Shanghai 91
Lauterbourg 87
Rome 77
Bologna 75
San Diego 74
Moscow 72
Fremont 62
Sofia 61
Princeton 60
Frankfurt am Main 58
Orem 52
Redwood City 52
São Paulo 52
Tokyo 46
Eugene 44
Buffalo 42
Columbus 41
Dong Ket 41
Salt Lake City 40
Warsaw 39
Baghdad 38
Izmir 37
Guangzhou 34
Bremen 33
Enfield 32
Phoenix 31
Parma 30
Reggio Emilia 30
Toronto 30
Mumbai 29
Brooklyn 26
San Giuliano Milanese 26
Da Nang 25
Elk Grove Village 25
Falls Church 25
Paris 25
Portsmouth 25
Tampa 25
Redondo Beach 24
Lawrence 22
Asyut 21
Boardman 21
Brussels 21
Nuremberg 21
Denver 20
Chennai 19
Montreal 19
Amsterdam 18
Dhaka 18
Florence 18
Haiphong 18
Johannesburg 18
Santiago 18
Atlanta 17
Kent 17
Miami 17
Poplar 17
Turku 17
Des Moines 16
Mexico City 16
Belo Horizonte 15
Cardiff 15
Nairobi 15
Palermo 15
Rio de Janeiro 15
Totale 14.433
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 606
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 451
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 416
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 402
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 396
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 383
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 383
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 378
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 374
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 362
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 361
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 357
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 350
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 348
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 347
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 338
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 332
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 328
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 327
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 324
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 319
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 316
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 315
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 313
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 309
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 309
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 308
Immune characterization of breast cancer metastases: prognostic implications. 306
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 302
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 297
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 288
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 286
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 284
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 282
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 281
PROFILO MUTAZIONALE DI TUMORI MAMMARI HER2 POSITIVI TRATTATI CON CHEMIOTERAPIA NEOADIUVANTE​ 280
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 277
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 277
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis. 275
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 270
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 266
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 261
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 258
Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. 255
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 254
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges 251
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 249
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 248
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 246
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. 233
The role of exosomes in breast cancer diagnosis 233
Breast cancer follow-up: a national survey of current clinical practice by the centers of Italian Oncological Group of Clinical Research (GOIRC). 232
TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis 230
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature 226
Adjuvant exemestane or tamoxifen plus ovarian suppression in premenopausal women: single institution analysis 224
Lapatinib and renal impairment: a case report 224
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. 223
Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it! 219
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 215
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 212
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 210
Next Generation Sequencing (NGS): a possible game changer in metastatic breast cancer 207
EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project 206
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 204
Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study. 200
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 195
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affectclinical outcome of metastatic breast cancer patients 191
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 191
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 182
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 179
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes 165
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 163
Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist 161
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 155
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer (HR+/HER2- mBC): regulatory aspects and clinical impact in Europe 151
Atezolizumab-Related Sarcoidosis-Like Reaction in Early Breast Cancer Patient: Know It To Diagnose It: A Case Report with Review of the Literature 150
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. 145
Pneumonitis and pulmonary fibrosis associated with breast cancer treatments 126
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 126
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 101
Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer 85
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials. BMC Cancer 9
Totale 21.718
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.426
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.426
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021159 0 0 0 0 0 0 0 0 0 0 0 159
2021/20221.368 77 147 117 58 51 110 63 71 131 126 251 166
2022/20232.647 191 266 146 186 174 202 47 156 960 50 168 101
2023/20241.418 75 64 100 136 175 128 160 211 54 64 101 150
2024/20254.110 140 53 126 265 805 585 317 252 402 282 330 553
2025/20268.014 558 243 912 788 1.098 503 1.036 437 801 780 708 150
Totale 21.718